Levitra news | Breaking Levitra news

Bayer's share price falls on 4Q results

...Meanwhile, MaterialScience grew 16% to 2.78 billion euros, although CropScience saw a decline of 5% compared to fourth-quarter 2004, at 1.38 billion euros.Bayer's chief executive Werner Wenning said in 2006 sales would rise by around 5% and there would be a slight increase in earnings.

He reiterated the view that two of Bayer's new drugs, Nexavar (sorafenib) for non-small cell lung cancer and the oral Factor Xa inhibitor for thrombotic diseases, could both top a billion euros in sales.

For the full-year, sales rose 18% to 27.4 billion euros, while net income jumped 133% to 1.6 billion euros.

More details from Bayer's annual results conference will be reported tomorrow.

Relevant Newsonline articles:Bayer expects net income of 1.6B euros for 2005Bayer starts second pivotal trial of alfimepraseBayer/Onyx start Ph III trial of Nexavar for NSCLCBayer's Trasylol linked to kidney failureBayer buys Pritor business from GSKNexavar cleared in USA for kidney cancerBayer upbeat at R&D showcaseBayer soars in Q3 on OTC boostOther sources:http://www.bayer.comemail this pageback to headlines disclaimer site design by DJM ...

Levitra

News

Advertisers:

Bayer's share price falls on 4Q results